Understanding Percent Tissue Altered as a Risk Factor for Ectasia After Excimer Laser Surgery

Marcony R. Santhiago, MD, PhD

Show Description +

Catch up on 10 years of research with Marcony R. Santhiago, MD, PhD, demonstrating that percent tissue altered is a strong risk factor for post-LASIK ectasia.

Posted: 9/11/2019

Keywords:

Corneal Ectasia

•

Ectasia

•

Post-LASIK ectasia

Up Next

Name: Understanding Percent Tissue Altered as a Risk Factor for Ectasia After Excimer Laser Surgery
Uploaded: 2019-09-11T16:27:00+00:00
Description: Catch up on 10 years of research with Marcony R. Santhiago, MD, PhD, demonstrating that percent tissue altered is a strong risk factor for post-LASIK ectasia.

Clinical Use of Cenegermin-bkbj Ophthalmic Solution for NK

Giacomina Massaro-Giordano, MD

Residual Astigmatism After Toric IOL Implantation

George O. Waring IV, MD, FACS

Surgery for Normal-Pressure Glaucoma: Is There a Role for MIGS Before Filtering Surgery?

Leonard K. Seibold, MD,

How Much Medication Is Too Much?

Janet Serle, MD

Iridocorneal Endothelial Syndrome

Lauren S. Blieden, MD

Managing Intraoperative Cataract Surgery Complications in Eyes With Glaucoma

Shakeel Shareef, MD

Key Results From the Bimatoprost SR Phase 3 Study

Randy Craven, MD

Gender Equality Strategies in Today's Workforce

Luxme Hariharan, MD

Social Media for Ophthalmologists

Ashley Brissette, MD

Evaluating Visual Performance of Small-Aperture, Accommodating, and Multifocal IOLs

Jay S. Pepose, MD, PhD

$Advanced Diagnostics in Refractive Surgery: Epithelial Mapping and Phakic IOL Sizing$

Advanced Diagnostics in Refractive Surgery: Epithelial Mapping and Phakic IOL Sizing

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

IOL Implantation in the Absence of Zonular Support

Joanne F. Shen, MD

Starting a Career as a Clinician Scientist in Ophthalmology

Alex Huang, MD

Mindfulness and Movement for Ophthalmologists

Jullia A. Rosdahl, MD, PhD

Top Ophthalmic Applications to Use in Your Practice

Lisa Nijm, MD, JD

Preventing Vision Loss in Keratoconus

Michael W. Belin, MD

Efficacy of Presbyond for the Correction of Presbyopia

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Autonomous AI in Ophthalmology

Michael D. Abramoff, MD, PhD

CXL for Infectious Keratitis

Farhad Hafezi, MD, PhD, FARVO

MIGS and Medications

Alex Huang, MD

Controlling Wound Healing Following PRK

Farhad Hafezi, MD, PhD, FARVO

MIGS in Patients With Corneal Disease

John P. Berdahl, MD

The Latest Trends in Dry Eye Disease Management

Audrey R. Talley Rostov, MD

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS

Hypersonic Vitrectomy Update

Carl C. Awh, MD

Iris Pigmented Tumors: When to Worry

Carol L. Shields, MD

Surgical Repair of Retinal Detachment

Mark W. Johnson, MD

PANORAMA Study Data

Rishi P. Singh, MD

Gene Therapy for Wet AMD

Szilard Kiss, MD

Anti-VEGF for Radiation Retinopathy

Amy C. Schefler, MD

Anatomy and Function in Major Comparative Trials

Usha Chakravarthy, MBBS, PhD

ABC to Block VEGF-A Isoforms

Charles C. Wykoff, MD, PhD

Surgery for Viral Retinitis